Evidence map›Paper›PMID 31437241›Full record

ArticlePloS one2019

Enhanced myelopoiesis and aggravated arthritis in S100a8-deficient mice.

Annabelle Cesaro, Joan Defrêne, Asmaa Lachhab, Nathalie Pagé, Mélanie R Tardif, Amin Al-Shami, Tamas Oravecz, Paul R Fortin, Jean-François Daudelin, Nathalie Labrecque and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. S100A9: The Unusual Suspect Connecting Viral Infection and Inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Annabelle CesaroAxe de recherche sur les maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec-Université Laval, Quebec city, Quebec, Canada.
Joan DefrêneAxe de recherche sur les maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec-Université Laval, Quebec city, Quebec, Canada.ORCID 0000-0002-8484-5857
Asmaa LachhabAxe de recherche sur les maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec-Université Laval, Quebec city, Quebec, Canada.
Nathalie PagéAxe de recherche sur les maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec-Université Laval, Quebec city, Quebec, Canada.
Mélanie R TardifAxe de recherche sur les maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec-Université Laval, Quebec city, Quebec, Canada.
Amin Al-ShamiLexicon Pharmaceuticals, Inc., The Woodlands, Texas, United States of America.
Tamas OraveczLexicon Pharmaceuticals, Inc., The Woodlands, Texas, United States of America.
Paul R FortinAxe de recherche sur les maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec-Université Laval, Quebec city, Quebec, Canada.
Jean-François DaudelinMaisonneuve-Rosemont Hospital Research Centre, Montreal, Quebec, Canada.
Nathalie LabrecqueMaisonneuve-Rosemont Hospital Research Centre, Montreal, Quebec, Canada.
Fawzi AoudjitAxe de recherche sur les maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec-Université Laval, Quebec city, Quebec, Canada.
Martin PelletierAxe de recherche sur les maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec-Université Laval, Quebec city, Quebec, Canada.
Philippe A TessierAxe de recherche sur les maladies infectieuses et immunitaires, Centre de recherche du CHU de Québec-Université Laval, Quebec city, Quebec, Canada.ORCID 0000-0001-7177-7763
Université Laval · CAHôpital Maisonneuve-Rosemont · CALexicon Pharmaceuticals (United States) · US

Funding

CIHR 136975CIHR 143057
6 · The paper itself

Abstract

Expressed strongly by myeloid cells, damage-associated molecular pattern (DAMP) proteins S100A8 and S100A9 are found in the serum of patients with infectious and autoimmune diseases. Compared to S100A9, the role of S100A8 is controversial. We investigated its biological activity in collagen-induced arthritis using the first known viable and fertile S100a8-deficient (S100a8-/-) mouse. Although comparable to the wild type (WT) in terms of lymphocyte distribution in blood and in the primary and secondary lymphoid organs, S100a8-/- mice had increased numbers of neutrophils, monocytes and dendritic cells in the blood and bone marrow, and these all expressed myeloid markers such as CD11b, Ly6G and CD86 more strongly. Granulocyte-macrophage common precursors were increased in S100a8-/- bone marrow and yielded greater numbers of macrophages and dendritic cells in culture. The animals also developed more severe arthritic disease leading to aggravated osteoclast activity and bone destruction. These findings were correlated with increased inflammatory cell infiltration and cytokine secretion in the paws. This study suggests that S100A8 is an anti-inflammatory DAMP that regulates myeloid cell differentiation, thereby mitigating the development of experimental arthritis.

Indexed as

MyelopoiesisAnimalsArthritis, ExperimentalBone and BonesBone MarrowCalgranulin ACartilageCell DifferentiationDendritic CellsFemaleGene DeletionMiceMyeloid CellsCalgranulin A

Identifiers

PMID31437241
PMCPMC6705798
OpenAlexW2969923799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.